Key Takeaways
- • AVANT BIO targets biotech infrastructure rather than therapeutic risk: Founding general partner Daniella Kranjac deploys capital into tools, technologies, and services that support biotech and pharma operations—a "picks and shovels" strategy that avoids direct exposure to drug development binary outcomes.
- • 26 years of operating experience informs investment thesis: Kranjac co-founded and bootstrapped her first company, scaled it, and sold to GE before running M&A at the conglomerate, bringing deep operational knowledge to her emerging growth equity fund.
- • Life sciences sector characterized as entering a "golden age": The SuperReturn International 2026 conference in Berlin brought together 2,000+ limited partners managing over $50 trillion in assets and 3,000+ general partners, signaling institutional conviction in the sector's momentum.
- • AI adoption remains nascent in pharma despite biotech sector momentum: Despite broader technological advancement, artificial intelligence integration into pharmaceutical workflows lags, presenting potential opportunity gaps for infrastructure-focused investors.
- • Emerging managers gaining traction at institutional forums: AVANT BIO's presence and activity at SuperReturn—one of the world's largest private equity and venture capital conferences—demonstrates market receptivity to specialized, thesis-driven emerging fund managers.
Summary
AVANT BIO, a newly formed growth equity firm founded by Daniella Kranjac, is pursuing a specialized investment strategy focused on the enablement infrastructure of the biotech and pharmaceutical sectors rather than therapeutic development itself. This approach—characterized internally as investing in the "invisible layer" or "picks and shovels" of biotech—targets the tools, technologies, and services that biotechnology and pharmaceutical companies depend upon to operate. The strategy deliberately sidesteps binary therapeutic risk, a distinguishing feature among emerging life sciences-focused managers.
Kranjac brings substantial credibility to her thesis through 26 years of direct life sciences experience that preceded her transition into capital deployment. She bootstrapped and scaled a company to successful acquisition by GE, then executed mergers and acquisitions strategy within the conglomerate's portfolio. This operating background—encompassing company founding, capital-efficient scaling, and exit execution—informs AVANT BIO's perspective on which infrastructure plays offer defensible competitive advantages and sustainable cash generation profiles.
The firm's emergence reflects broader institutional interest in life sciences investing. At SuperReturn International 2026 in Berlin, where Opalesque served as media partner, the conference assembled over 2,000 limited partners collectively managing in excess of $50 trillion in assets, alongside more than 3,000 general partners. Market participants characterized the current period as a "golden age" for life sciences investment, though notable technology adoption gaps persist—specifically, artificial intelligence integration into pharmaceutical workflows remains underdeveloped despite its advancement in adjacent sectors. This gap presents a potential thesis tailwind for infrastructure-focused investors who can identify and back enabling technologies that accelerate AI adoption across pharma operations.
AVANT BIO's positioning at SuperReturn, including Kranjac's participation in LP-focused programming, demonstrates institutional market receptivity to emerging managers with differentiated, operationally grounded investment frameworks. The firm's emergence exemplifies a broader institutional pattern: as capital allocators seek specialized exposure within large sectors, emerging managers with domain expertise and non-consensus positioning can establish credibility and attract capital at scale.
Kranjac brings substantial credibility to her thesis through 26 years of direct life sciences experience that preceded her transition into capital deployment. She bootstrapped and scaled a company to successful acquisition by GE, then executed mergers and acquisitions strategy within the conglomerate's portfolio. This operating background—encompassing company founding, capital-efficient scaling, and exit execution—informs AVANT BIO's perspective on which infrastructure plays offer defensible competitive advantages and sustainable cash generation profiles.
The firm's emergence reflects broader institutional interest in life sciences investing. At SuperReturn International 2026 in Berlin, where Opalesque served as media partner, the conference assembled over 2,000 limited partners collectively managing in excess of $50 trillion in assets, alongside more than 3,000 general partners. Market participants characterized the current period as a "golden age" for life sciences investment, though notable technology adoption gaps persist—specifically, artificial intelligence integration into pharmaceutical workflows remains underdeveloped despite its advancement in adjacent sectors. This gap presents a potential thesis tailwind for infrastructure-focused investors who can identify and back enabling technologies that accelerate AI adoption across pharma operations.
AVANT BIO's positioning at SuperReturn, including Kranjac's participation in LP-focused programming, demonstrates institutional market receptivity to emerging managers with differentiated, operationally grounded investment frameworks. The firm's emergence exemplifies a broader institutional pattern: as capital allocators seek specialized exposure within large sectors, emerging managers with domain expertise and non-consensus positioning can establish credibility and attract capital at scale.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.